Table 2.
Potential drug targets of the de novo assembled T. bryosalmonae transcripts
| Target protein (abbreviation; CHEMBL ID) (original publication) | Role in metabolism | Drug target in other parasites | Potential inhibitors from literature | Transcript ID | Average FPKM | E-value | Identity (%) | Alignment length (aa) |
|---|---|---|---|---|---|---|---|---|
| Endoglycoceramidase (EGCase; CHEMBL3112388) (Ishida et al., 2014) | Lipid digestion | None | Cellobiose-like imidazole and iminocyclitol inhibitors (Caines et al., 2007) | DN11176_c0_g2_i1 (EGCase1) | 185.3 | 6.97×10−9 | 28.8 | 139 |
| DN1345_c0_g1_i1 (EGCase2) | 152.5 | 1.98×10−8 | 25.6 | 160 | ||||
| Legumain-like protease (LGMN; CHEMBL1075261) (Ovat et al., 2009) | Proteolytic (lysosomal) enzyme | Schistosoma mansoni (Ovat et al., 2009) and Trichomonas vaginalis (Rendón-Gandarilla et al., 2013) | Aza-Peptidyl Michael Acceptor and Epoxide selective inhibitors (Ovat et al., 2009). | DN3668_c0_g1_i1 | 193.5 | 2.86×10−6 | 24.5 | 139 |
| Carbonic anhydrase 2 (CA2; CHEMBL2331045) (Syrjänen et al., 2013) | Reversible hydration of carbon dioxide | Trypanosoma and Leishmania (protists) (Vermelho et al., 2017) and blood flukes, Schistosomes (Angeli et al., 2020) | Sulfonamide, thiol and hydroxamate inhibitors (Vermelho et al,. 2017; Angeli et al., 2020) | DN419_c0_g2_i1 | 105.2 | 5.29×10−5 | 31.6 | 114 |
| Pancreatic lipase-related protein 2 (PLRP2; CHEMBL2169729) (Point et al., 2012) | Lipid digestion | None but its inhibitor Orlistat has shown in vitro growth inhibition of a protist parasite Giardia duodenalis (Hahn et al., 2013) | Orlistat (lipase inhibitor) and Oxadiazolones (Point et al., 2012) | DN10075_c0_g2_i1 | 92.0 | 0.000355 | 26.8 | 112 |
| DN9655_c0_g2_i1 | 74.9 | 0.000418 | 22.2 | 149 |